These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3755382)

  • 1. Evaluation of sustained-release capsules of molsidomine (SIN-10) in dogs and monkeys.
    Morimoto M; Yamashita K; Koyama H; Fujimoto H; Toguchi H; Kitamori N
    Chem Pharm Bull (Tokyo); 1986 Mar; 34(3):1257-63. PubMed ID: 3755382
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hemodynamic effect of molsidomine in acute administration and as a long-term medication].
    Osterspey A; Jansen W; Tauchert M; Schell U; Fuchs M; Hombach V; Hilger HH
    Med Welt; 1983 Apr; 34(17):523-8. PubMed ID: 6408341
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetics of molsidomine in humans.
    Ostrowski J; Resag K
    Am Heart J; 1985 Mar; 109(3 Pt 2):641-3. PubMed ID: 3838399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of molsidomine on coronary artery thrombosis and myocardial ischemia in acute canine experiments.
    Fiedler VB
    Eur J Pharmacol; 1981 Jul; 73(1):85-9. PubMed ID: 6895623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diameter changes of epicardial coronary arteries and coronary stenoses after intracoronary application of SIN 1, a molsidomine metabolite].
    Schulz W; Wendt T; Scherer D; Kober G
    Z Kardiol; 1983 Jul; 72(7):404-9. PubMed ID: 6613236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of metoprolol with molsidomine in the treatment of angina pectoris.
    van Mantgem JP; Lie KI; Matroos AW
    Eur J Clin Pharmacol; 1985; 28(2):109-11. PubMed ID: 3838725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between pharmacokinetics and pharmacodynamics of molsidomine and its metabolites in humans.
    Meinertz T; Brandstätter A; Trenk D; Jähnchen E; Ostrowski J; Gärtner W
    Am Heart J; 1985 Mar; 109(3 Pt 2):644-8. PubMed ID: 3838400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of the vasodilator molsidomin in the treatment of chronic cardiac insufficiency].
    Mareev VIu; Sazonova LN; Grigor'iants RA; Lobova NM; Irani RM
    Ter Arkh; 1983; 55(9):76-80. PubMed ID: 6688891
    [No Abstract]   [Full Text] [Related]  

  • 9. The influence of molsidomine and its active metabolite SIN-1 on fibrinolysis and platelet aggregation.
    Basista M; Grodzińska L; Swies J
    Thromb Haemost; 1985 Dec; 54(4):746-9. PubMed ID: 3911480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of an extended-release dosage form of molsidomine in patients with coronary heart disease.
    Ostrowski J; Gaul G; Voegele D; Brockmeier D; Resag K
    Eur J Clin Pharmacol; 1985; 28(5):611-3. PubMed ID: 3899679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hypotension induced by molsidomine or trinitroglycerin].
    Dassier P; Blanloeil Y; Pinaud M; Bodin D; Vandeville B
    Cah Anesthesiol; 1985; 33(4):309-13. PubMed ID: 3931864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous and oral administration of molsidomine, a pharmacodynamic and pharmacokinetic study.
    Bergstrand R; Vedin A; Wilhelmsson C; Peterson LE; Chamberlain J; Dell D; Stevens LA; Ostrowski J
    Eur J Clin Pharmacol; 1984; 27(2):203-8. PubMed ID: 6548711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment of patients with coronary heart disease using isosorbide dinitrate, nifedipine and molsidomine.
    Jansen W; Tauchert M; Osterspey A; Hombach V; Fuchs M; Hilger HH
    Z Kardiol; 1983; 72 Suppl 3():203-10. PubMed ID: 6689389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unloading effects of molsidomine on peripheral circulation and cardiac hemodynamics in patients with acute myocardial infarction.
    Seino Y; Vyden JK; Rose HB; Takano T; Obayashi K; Hayakawa H; Kimura E
    Angiology; 1983 Aug; 34(8):535-45. PubMed ID: 6688506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SIN-1, the main metabolite of molsidomine, inhibits prostaglandin endoperoxide analogue- and arachidonic acid-induced platelet aggregation as well as platelet thromboxane A2 formation.
    Block HU; Förster W; Heinroth I
    Arzneimittelforschung; 1982; 32(3):189-94. PubMed ID: 6896278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absorption and disposition of [14C]-molsidomine in laboratory animals.
    Fromson JM; Illing HP; Ings RM; Johnson KI; Johnson P; Ostrowski J; Schraven E; Steward A
    Arzneimittelforschung; 1981; 31(2):337-45. PubMed ID: 6894378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of molsidomine, an anti-anginal drug, on arachidonic acid metabolism in human platelets.
    Croset M; Lagarde M
    Biomed Biochim Acta; 1984; 43(8-9):S354-7. PubMed ID: 6440549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of oral molsidomine effects on ventricular function and dimensions in the conscious dog.
    Fiedler VB; Göbel H; Nitz RE
    Arch Int Pharmacodyn Ther; 1983 Mar; 262(1):56-75. PubMed ID: 6409016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molsidomine: evaluation of a single dose using the exercise test].
    Ruano J; Zueco J; Colman T; López C; Pajarón A
    Rev Esp Cardiol; 1985; 38(2):93-7. PubMed ID: 3890039
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of molsidomine and other NO-containing vasodilators on cyclic GMP formation.
    Böhme E; Grossman G; Spies C
    Eur Heart J; 1983 May; 4 Suppl C():19-24. PubMed ID: 6311553
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.